Vista Pharmaceuticals (BOM:524711) Cyclically Adjusted PS Ratio: (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524711 Vista Pharmaceuticals Ltd BOM:524711
48 GF Score
Price ₹6.09
GF Value ₹4.49
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Vista Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vista Pharmaceuticals  (BOM:524711) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vista Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Vista Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Vista Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vista Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Vista Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.87 1.21 1.40 0.00

Vista Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.41 1.30 1.11 0.00 0.00

BOM:524711 vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vista Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vista Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vista Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vista Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BOM:524711
48GF Score
Vista Pharmaceuticals Ltd BOM:524711
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vista Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vista Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Vista Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Vista Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.442 105.961 3.857
201612 2.462 105.196 3.917
201703 2.049 105.196 3.260
201706 2.724 107.109 4.256
201709 2.292 109.021 3.518
201712 2.514 109.404 3.846
201803 2.342 109.786 3.570
201806 2.282 111.317 3.431
201809 1.909 115.142 2.775
201812 2.362 115.142 3.433
201903 3.246 118.202 4.596
201906 2.278 120.880 3.154
201909 2.412 123.175 3.277
201912 2.220 126.235 2.943
202003 0.241 124.705 0.323
202006 0.000 127.000 0.000
202009 0.125 130.118 0.161
202012 0.104 130.889 0.133
202103 0.129 131.771 0.164
202106 0.000 134.084 0.000
202109 0.078 135.847 0.096
202112 0.029 138.161 0.035
202203 0.000 138.822 0.000
202206 0.000 142.347 0.000
202209 0.000 144.661 0.000
202212 0.000 145.763 0.000
202303 0.209 146.865 0.238
202306 0.477 150.280 0.531
202309 0.790 151.492 0.873
202312 0.345 152.924 0.378
202403 0.668 153.035 0.731
202406 0.314 155.789 0.337
202409 0.410 157.882 0.435
202412 0.415 158.323 0.439
202503 0.525 157.552 0.558
202506 0.259 159.755 0.271
202509 0.237 162.289 0.244
202512 0.427 163.281 0.438
202603 0.000 164.272 0.000
202606 0.000 167.357 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Vista Pharmaceuticals (BOM:524711) Overvalued in 2026?

Based on GuruFocus' analysis, Vista Pharmaceuticals stock appears to be overvalued. The current stock price of ₹6.09 is trading 35.6% above its estimated GF Value™ of ₹4.49. GuruFocus considers Vista Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524711:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: ₹4.49 vs. price of ₹6.09 (35.6% above fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the BOM:524711 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vista Pharmaceuticals Business Description

Address Kakateeya Hills, Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet, Hyderabad, TG, IND, 500033
Vista Pharmaceuticals Ltd is an Indian company engaged in a single operating segment, which is the manufacturing of Pharmaceutical products. The company offers over-the-counter and prescription generic drug products such as tablets, capsules, and liquids covering various therapeutic categories. Some of the drugs in tablet dosage forms are Sulfamethoxazole and Trimethoprim, Bismuth Subgallate, Pyrantel Pamoate, Aspirin, Ibuprofen, Ranitidine HCl, and others. Nifedipine, Piroxicam, and Indomethacin are the drugs offered by the company in a capsule dosage form. The company generates all of its operating revenue from sales within its domestic market.
48GF Score

Get the complete analysis for BOM:524711

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6.09
Price
₹4.49
GF Value